Hashino K, Ishii M, Iemura M, Akagi T, Kato H
Department of Pediatrics, Kurume University School of Medicine, Kurume, Japan.
Pediatr Int. 2001 Jun;43(3):211-7. doi: 10.1046/j.1442-200x.2001.01373.x.
We compared the efficacy and safety of additional intravenous immune globulin (IVIG) therapy with steroid pulse therapy in patients with IVIG-resistant Kawasaki disease.
Two-hundred and sixty-two consecutive patients had been treated with a single dose of IVIG (2 g/kg) and aspirin (30 mg/kg per day). Thirty-five patients (13.4%) were not clinical responders to the initial IVIG treatment. They received an additional IVIG treatment (1 g/kg) within 48 h after the initial treatment. Seventeen patients (6.5%) did not respond to the additional IVIG treatment. We randomly divided these patients into two groups: group 1 consisted of eight patients who were treated with a single additional dose of IVIG (1 g/kg), while group 2 consisted of nine patients who were treated with steroid pulse therapy.
The IVIG-resistant patients had a high incidence of coronary artery lesions (CAL; 48.6%). Five patients (62.5%) in group 1 had CAL, including two patients who each had a giant aneurysm and three patients who each had a small aneurysm. Seven patients (77.8%) in group 2 had CAL, including two patients who each had a giant aneurysm, two patients who each had a small coronary aneurysm and three patients who each showed transient dilatation during steroid pulse therapy. There was no significant difference in the incidence of CAL between the two groups. The duration of high fever in group 2 (1.40.7 days) was significantly shorter than in group 1 (4.83.4 days; P<0.05). The medical costs for the treatment of patients in group 2 (113, 012 yen +/- 22,084) were significantly lower than those for group 1 (144,194 yen +/- 12,914; P<0.05).
Steroid pulse therapy may be useful in the treatment of patients with IVIG-resistant Kawasaki disease who experience prolonged fever. However, transient dilatation of the coronary artery is observed during steroid pulse therapy, so careful echocardiographic examination should be performed for those patients receiving steroid pulse therapy for the sake of early detection of coronary artery abnormalities.
我们比较了静脉注射免疫球蛋白(IVIG)辅助治疗与类固醇脉冲疗法对IVIG抵抗型川崎病患者的疗效和安全性。
连续262例患者接受了单剂量IVIG(2 g/kg)和阿司匹林(每日30 mg/kg)治疗。35例患者(13.4%)对初始IVIG治疗无临床反应。他们在初始治疗后48小时内接受了额外的IVIG治疗(1 g/kg)。17例患者(6.5%)对额外的IVIG治疗无反应。我们将这些患者随机分为两组:第1组由8例接受单次额外剂量IVIG(1 g/kg)治疗的患者组成,而第2组由9例接受类固醇脉冲疗法治疗的患者组成。
IVIG抵抗型患者冠状动脉病变(CAL)发生率较高(48.6%)。第1组中有5例患者(62.5%)发生CAL,其中2例各有一个巨大动脉瘤,3例各有一个小动脉瘤。第2组中有7例患者(77.8%)发生CAL,其中2例各有一个巨大动脉瘤,2例各有一个小冠状动脉瘤,3例在类固醇脉冲治疗期间出现短暂扩张。两组之间CAL的发生率没有显著差异。第2组的高热持续时间(1.40.7天)明显短于第1组(4.83.4天;P<0.05)。第2组患者的治疗费用(113,012日元±22,084)明显低于第1组(144,194日元±12,914;P<0.05)。
类固醇脉冲疗法可能对IVIG抵抗型川崎病且发热持续时间较长的患者有用。然而,在类固醇脉冲治疗期间观察到冠状动脉短暂扩张,因此对于接受类固醇脉冲疗法的患者应进行仔细的超声心动图检查,以便早期发现冠状动脉异常。